News
- Author:
- Randy Dotinga
Publish date: October 18, 2023
Neurologists outline findings as the MS field works toward consensus on HSCT as rescue therapy.
News
- Author:
- Randy Dotinga
Publish date: October 16, 2023
The VA could save nearly $10,000 annually per patient in the Mountain West re...
News
- Author:
- Randy Dotinga
Publish date: October 16, 2023
Identification of a reliable MS biomarker as well as early detection and intervention will be key going forward.
News
- Author:
- Randy Dotinga
Publish date: October 16, 2023
Results from several treatment trials in progressive MS are expected over the next 2 years.
News
- Author:
- Randy Dotinga
Publish date: October 13, 2023
Choices depend on factors like evidence of disease, radiologists say.
News
- Author:
- Randy Dotinga
Publish date: October 13, 2023
Subjects with excess weight progressed more rapidly and had more cognitive disability.
News
- Author:
- Randy Dotinga
Publish date: October 13, 2023
It’s still not clear when – or if – certain patients should take a break from MS therapy.
News
- Author:
- Randy Dotinga
Publish date: October 11, 2023
Hematologists say that median lifespans are reaching 10 years or more after diagnosis.
News
- Author:
- Randy Dotinga
Publish date: October 11, 2023
A new report offers a picture of patients seeking care for breast and gynecol...
News
- Author:
- Randy Dotinga
Publish date: October 11, 2023
Weakened bioavailability of mycophenolate mofetil could require adjustments in treatment.
News
- Author:
- Randy Dotinga
Publish date: October 6, 2023
At 10 years, partial-breast/reduced-dose therapy are still noninferior to whole-breast approach.
News
- Author:
- Randy Dotinga
Publish date: October 5, 2023
“We need more technical details to understand how to deliver this regimen in clinical practice, and it may not be applicable for all patients.”
News
- Author:
- Randy Dotinga
Publish date: October 4, 2023
The use of the higher-dose approach, known as hypofractionation, “resulted in fewer treatment breaks and less financial toxicity.”
News
- Author:
- Randy Dotinga
Publish date: October 4, 2023
“We found surprisingly that SABR delayed a change in therapy by 10 months, which is great for patients.”
News
- Author:
- Randy Dotinga
Publish date: October 4, 2023
Sexual intercourse and dilator use may reduce risk of vaginal stenosis following treatment for cervical cancer.
